

## Supplementary

**Table S1** Outcomes

Endpoint	Afatinib (n=15)	Osimertinib (n=71)	P
PFS (months)	27.9 (19.2, NE)	29.0 (20.2, NE)	0.75
OS (months)	NE (64.2, NE)	NE (27.2, NE)	0.18
Time on first-line TKI (months)	23.9 [0.4, 75.4]	15.2 [0.8, 47.7]	0.10

Data are presented as median (95% CI) or median [range]. PFS, progression-free survival; NE, not estimable; OS, overall survival; TKI, tyrosine kinase inhibitor; CI, confidence interval.

**Table S2** PFS and OS stratified by mutational status

Endpoint	Exon 19 deletion (n=66)	Exon 21 L858R (n=20)	P
PFS (months)	27.1 (19.5, NE)	26.6 (25.4, NE)	0.35
OS (months)	64.2 (27.2, NE)	NE	0.26

Data are presented as median (95% CI). PFS, progression-free survival; OS, overall survival; NE, not estimable; CI, confidence interval.